Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00121745 · ClinicalTrials.gov registry record · Phase 1
Evaluation of Safety of Rexin-G Gene Transfer for Advanced Pancreatic Cancer
A Phase 1 study, sponsored by Epeius Biotechnologies.
- Terminated
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT00121745: Clinical Trial Phase 1 study, sponsored by Epeius Biotechnologies.
NCT00121745 is a Phase 1 study that was terminated before completion, run by Epeius Biotechnologies. The registered enrollment target is 12 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00121745, a Phase 1 study, was terminated before completion, sponsored by Epeius Biotechnologies.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This is a dose-seeking study that will test the safety of increasing doses of Rexin-G, given intravenously, in patients with advanced or metastatic pancreatic cancer who have failed standard chemotherapy. Rexin-G is a tumor-targeted gene therapy vector that contains a "killer" gene that blocks the action of the human cyclin G1 gene. Cyclin G1 is a cell cycle control element that plays an important role in cancer growth. When injected into a vein, the Rexin-GTM vector seeks out and accumulates in cancerous tumors, therefore, increasing the concentration of the drug in the cancerous tumors and not in normal neighbouring organs.
Interventions
- GENETIC Rexin-G Dose 1
- GENETIC Rexin-G Dose 2
- GENETIC Rexin-G Dose 3
- GENETIC Rexin-G Dose 4
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2005-07 |
| Est. Completion | 2007-07 |
| Phase | Phase 1 |
Why NCT00121745 stopped before completion
NCT00121745 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower).
The record links to 0 conditions, and to 4 interventions - of which Rexin-G Dose 1 is the first listed.
NCT00121745 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00121745 about?
NCT00121745 is a clinical study titled "Evaluation of Safety of Rexin-G Gene Transfer for Advanced Pancreatic Cancer". This is a dose-seeking study that will test the safety of increasing doses of Rexin-G, given intravenously, in patients with advanced or metastatic pancreatic cancer who have failed standard chemotherapy. Rexin-G is a tumor-targeted gene therapy vector that contains a "killer" gene that blocks the a...
What is the current status of trial NCT00121745?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2005-07. Estimated completion is 2007-07.
What interventions are being tested in trial NCT00121745?
The interventions under investigation include: Rexin-G Dose 1 (GENETIC), Rexin-G Dose 2 (GENETIC), Rexin-G Dose 3 (GENETIC), Rexin-G Dose 4 (GENETIC).
Who is sponsoring clinical trial NCT00121745?
This trial is sponsored by Epeius Biotechnologies, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00121745's enrollment target sits among peer trials
12 1852nd of 2000 higher than 90 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia